Our Science

Innovating for Patients

Proteins that misfold and aggregate to form amyloid are associated with more than 25 human diseases that can gravely damage organs. Amyloid can affect any organ in the body, including the brain and peripheral organs.

We optimally target misfolded proteins to achieve clinical benefit across a number of indications, focusing on proteins like tau, alpha-synuclein, and transthyretin.

Decades of our own scientific investigation augmented by the work of others have elucidated that antibody therapeutics can result in meaningful clinical benefit for patients with the right combination of targeting the appropriate epitope, optimal binding strength, and the right clinical trial design with the appropriate endpoints in the right patient population.

While we are modality agnostic, we have deep expertise in antibody targeting and leverage insights and understanding around neurological dysfunction and the biology of misfolded proteins to develop a diverse pipeline.

Learn more about Prothena’s pipeline